NCT05104216Unknown4 期
Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and Chronic Obstructive Pulmonary Disease
适应症
试验速览
- 阶段
- 4 期
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Seroconversion rate
研究概览
简要总结
Evaluation of immunogenicity, safety and persistence of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease received the third dose of inactivated COVID-19 vaccine .
详细描述
The subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease recruited to receive a third dose of inactivated COVID-19 vaccine.
Blood samples will be collected 3 times: before the third dose of vaccinatioin，28 days and 6 months after the third dose of vaccination.
Any local or systemic adverse events that occurred within 21 days after vaccination will be recorded.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects aged 60 and above with full capacity for civil conduct;
- •Chronic bronchitis (or chronic obstructive pulmonary disease) diagnosed by a medical institution at level I or above;
- •Body temperature < 37.3 ° C confirmed by clinical examination before enrollment ;
- •Able and willing to complete the entire study plan during the study follow-up period;
- •Have the ability to understand the study procedures, voluntarily sign informed consent, and comply with the requirements of the clinical study protocol;
- •Subjects participating in the past clinical trial have completed two doses of COVID-19 vaccine and blood collection before and after immunization;
排除标准
- •Subjects were previously confirmed cases of COVID-19 or asymptomatic infected persons;
- •Being allergic to any component of vaccines (including excipients) ;
- •Injection of non-specific immunoglobulin within 1 month before enrollment;
- •Injection of live attenuated vaccines within 1 month and injection of other vaccines within 14 days before enrollment;
- •Subjects who have experienced severe allergic reactions to vaccines (e.g. acute anaphylaxis, urticaria, angioneurotic edema, dyspnea, etc.);
- •Having uncontrolled epilepsy and other progressive neurological disorders and a history of Guillain-Barre syndrome;
- •Having severe liver and kidney diseases, malignant tumors, acute diseases or acute episodes of chronic diseases;
- •Have been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukaemia or other autoimmune diseases;
- •Have been diagnosed with thrombocytopenia or other clotting disorders that may contraindicate subcutaneous injection;
- •During an acute episode of chronic bronchitis/chronic obstructive pulmonary disease;
- •Subjects who had vaccine-related adverse reactions after the second dose;
- •Having high fever (axillary temperature ≥39.0℃) for three days after the second dose of inoculation, or severe allergic reaction;
- •Having any adverse nervous system reaction after the second dose;
- •During the acute onset of a chronic disease, or the recovery of acute complications less than two weeks;
- •Other reasons for exclusion considered by the investigator.
结局指标
主要结局
Seroconversion rate
时间窗: 28 days after the 3th dose (Day 28)
The rate of seroconversion against coronavirus
Neutralizing antibody level
时间窗: 6 months after the 3th dose
Neutralizing antibody GMT against coronavirus after the 3th dose
次要结局
- Adverse events rate(0-21days following vaccinations)
- Serious adverse event rate(0-6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B VaccinesHepatitis bNCT01203319Jiangsu Province Centers for Disease Control and Prevention1,091
已完成
2 期
FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 YearsEncephalitis, Tick-borneNCT00161850Pfizer615
已完成
2 期
FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 YearsEncephalitis, Tick-borneNCT00161889Pfizer615
已完成
4 期
Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous DosePertussisWhooping CoughTetanusDiphtheriaNCT01439165Sanofi Pasteur, a Sanofi Company1,330
已完成
2 期
Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly SubjectsMyxovirus InfectionInfluenzaNCT00551031Sanofi2,098